Send to

Choose Destination
Indian J Pathol Microbiol. 2020 Feb;63(Supplement):S64-S69. doi: 10.4103/IJPM.IJPM_872_19.

Subtype specific biomarkers associated with chemoresistance in epithelial ovarian cancer.

Author information

Imaging Cell Signalling and Therapeutics Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai; Homi Bhabha National Institute, Anushakti Nagar, Maharashtra, India.
Homi Bhabha National Institute, Anushakti Nagar; Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai, Maharashtra, India.


In spite of the advent of many high throughput technologies, tumor tissue biomarkers are still the gold standard for diagnosis and prognosis of different malignancies including epithelial ovarian cancer (EOC). EOC is a heterogeneous disease comprised of five major subtypes which show distinct clinicopathological features and therapy response. Acquirement of chemoresistance toward therapy is a major challenge for successful treatment outcome in EOC patients. Several markers have been tested by immunohistochemical method to evaluate their prognostic merit to predict clinical outcome. However, a vast majority of such markers have been assessed for high-grade serous and clear cell ovarian cancer, among all subtypes of EOC. The current review elaborates upon those biomarkers that can potentially predict chemoresistance with subtype specificity.


Biomarkers; chemoresistance; epithelial ovarian cancer

Free full text

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd
Loading ...
Support Center